Use of multiattribute utility theory for formulary management in a health system
| Autor: | Kie-Ho Sohn, Jeongmee Kim, Seonyoung Chung, Sooyon Kim |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Drug
media_common.quotation_subject Decision Making Pharmacology Drug Costs Decision Theory Health care Medicine Humans Amlodipine Formulary Pharmacy and Therapeutics Committee Antihypertensive Agents media_common Actuarial science Korea business.industry United States Food and Drug Administration Health Policy Utility theory Calcium Channel Blockers Formularies Hospital as Topic United States Treatment Outcome Patient Satisfaction Drug analysis Safety business Olmesartan Factor Analysis Statistical Pharmacy Service Hospital Angiotensin II Type 1 Receptor Blockers Algorithms medicine.drug Healthcare system |
| Zdroj: | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 67(2) |
| ISSN: | 1535-2900 |
| Popis: | Purpose The application, utility, and flexibility of the multiattribute utility theory (MAUT) when used as a formulary decision methodology in a Korean medical center were evaluated. Methods A drug analysis model using MAUT consisting of 10 steps was designed for two drug classes of dihydropyridine calcium channel blockers (CCBs) and angiotensin II receptor blockers (ARBs). These two drug classes contain the most diverse agents among cardiovascular drugs on Samsung Medical Center’s drug formulary. The attributes identified for inclusion in the drug analysis model were effectiveness, safety, patient convenience, and cost, with relative weights of 50%, 30%, 10%, and 10%, respectively. The factors were incorporated into the model to quantify the contribution of each attribute. For each factor, a utility scale of 0–100 was established, and the total utility score for each alternative was calculated. An attempt was made to make the model adaptable to changing health care and regulatory circumstances. Results The analysis revealed amlodipine besylate to be an alternative agent, with the highest total utility score among the dihydropyridine CCBs, while barnidipine hydrochloride had the lowest score. For ARBs, losartan potassium had the greatest total utility score, while olmesartan medoxomil had the lowest. Conclusion A drug analysis model based on the MAUT was successfully developed and used in making formulary decisions for dihydropyridine CCBs and ARBs for a Korean health system. The model incorporates sufficient utility and flexibility of a drug’s attributes and can be used as an alternative decision-making tool for formulary management in health systems. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|